Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations

Cancer Cell

Volumn 7, Issue 2, 2005, Pages 179-191

  Mohi, M Golam ^a   Williams, Ifor R ^b   Dearolf, Charles R ^c   Chan, Gordon ^a   Kutok, Jeffery L ^d   Cohen, Sarah ^d   Morgan, Kelly ^d   Boulton, Christina ^d   Shigematsu, Hirokazu ^e   Keilhack, Heike ^a   Akashi, Koichi ^e   Gilliland, D Gary ^d   Neel, Benjamin G ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GAB2; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DROSOPHILA; ENZYME ACTIVATION; FEMALE; GENETIC TRANSDUCTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; SOMATIC MUTATION; SRC HOMOLOGY DOMAIN;

ANIMALIA; MURINAE;

EID: 13844265841     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.01.010     Document Type: Article

References (77)

1. Y.M. Agazie, and M.J. Hayman Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling Mol. Cell. Biol. 23 2003 7875 7886
2. K. Akashi, D. Traver, T. Miyamoto, and I.L. Weissmann A clonogenic common myeloid progenitor that gives rise to all myeloid lineages Nature 404 2000 193 197
3. T. Araki, H. Nawa, and B.G. Neel Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors J. Biol. Chem. 278 2003 41677 41684
4. T. Araki, M.G. Mohi, F.A. Ismat, R.T. Bronson, I.R. Williams, J.L. Kutok, W. Yang, L.I. Pao, D.G. Gilliland, J.A. Epstein, and B.G. Neel Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation Nat. Med. 10 2004 849 857
5. M. Arico, A. Biondi, and C.-H. Pui Juvenile myelomonocytic leukemia Blood 90 1997 479 488
6. S.A. Armstrong, T.R. Golub, and S.J. Korsmeyer MLL-rearranged leukemias: Insights from gene expression profiling Semin. Hematol. 40 2003 268 273
7. H. Asha, I. Nagy, G. Kovacs, D. Stetson, I. Ando, and C.R. Dearolf Analysis of Ras-induced overproliferation in Drosophila hemocytes Genetics 163 2003 203 215
8. B. Bader-Meunier, G. Tchernia, F. Mielot, J.L. Fontaine, C. Thomas, S. Lyonnet, J.M. Lavergne, and J.P. Dommergues Occurrence of myeloproliferative disorder in patients with Noonan syndrome J. Pediatr. 130 1997 885 889
9. D. Barford, and B.G. Neel Revealing mechanisms for SH2 domain-mediated regulation of the protein tyrosine phosphatase SHP-2 Structure 6 1998 249 254
10. A. Bennett, T. Tang, S. Sugimoto, C. Walsh, and B. Neel Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras Proc. Natl. Acad. Sci. USA 91 1994 7335 7339
11. M. Bentires-Alj, J.G. Paez, F.S. David, H. Keilhack, B. Halmos, K. Naoki, J.M. Maris, A. Richardson, A. Bardelli, and D.J. Sugarbaker Activating mutations of the Noonan Syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult AML Cancer Res. 64 2004 8816 8820
12. M.A. Bjornsti, and P.J. Houghton The TOR pathway: A target for cancer therapy Nat. Rev. Cancer 4 2004 335 348
13. G. Bollag, D.W. Clapp, S. Shih, F. Adler, Y. Zhang, P. Thompson, B.J. Lange, M.H. Freedman, F. McCormic, T. Jacks, and K.M. Shannon Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells Nat. Genet. 12 1996 144 148
14. A.H. Brand, and P. Perrimon Targeted gene expression as a means of altering cell fates and generating dominant phenotypes Development 118 1993 401 415
15. B.S. Braun, D.A. Tuveson, N. Kong, D.T. Le, S.C. Kogan, J. Rozmus, M.M. Le Beau, T.E. Jacks, and K.M. Shannon Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder Proc. Natl. Acad. Sci. USA 101 2004 597 602
16. I.T. Chan, J.L. Kutok, I.R. Williams, S. Cohen, L. Kelly, H. Shigematsu, L. Johnson, K. Akashi, D.A. Tuveson, T. Jacks, and D.G. Gilliland Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease J. Clin. Invest. 113 2004 528 538
17. K. Choong, M.H. Freedman, D. Chitayat, E.N. Kelly, G. Taylor, and A. Zipursky Juvenile myelomonocytic leukemia and Noonan Syndrome J. Pediatr. Hematol. Oncol. 21 1999 523 527
18. K. Cichowski, S. Santiago, M. Jardim, B.W. Johnson, and T. Jacks Dynamic regulation of the ras pathway via proteolysis of the NF1 tumor suppressor Genes Dev. 17 2003 449 454
19. N.C. Cross, and A. Reiter Tyrosine kinase fusion genes in chronic myeloproliferative diseases Leukemia 16 2002 1207 1212
20. C.R. Dearolf Fruit fly "leukemia." Biochim. Biophys. Acta 1377 1998 M13 M23
21. J.E. Denu, J.A. Stuckey, M.A. Saper, and J.E. Dixon Form and function in protein dephosphorylation Cell 87 1996 361 364
22. S. Donovan, W. See, J. Bonifas, D. Stokoe, and K.M. Shannon Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation and cytokine expression in Nf1-deficient myeloid cells Cancer Cell 2 2002 507 514
23. P.D. Emanuel, K.M. Shannon, and R.P. Castleberry Juvenile myelomonocytic leukemia: Molecular undrestanding and prospects for therapy Mol. Med. Today 2 1996 468 475
24. A.J. Flint, T. Tiganis, D. Barford, and N.K. Tonks Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases Proc. Natl. Acad. Sci. USA 94 1997 1680 1685
25. R.M. Freeman Jr., J. Plutzky, and B.G. Neel Identification of a human src-homology 2 (SH2) containing tyrosine phosphatase: A putative homolog of Drosophila corkscrew Proc. Natl. Acad. Sci. USA 89 1992 11239 11243
26. D.G. Gilliland, and J.D. Griffin Role of FLT3 in leukemia Curr. Opin. Hematol. 9 2002 274 281
27. D.G. Gilliland, and M.S. Tallman Focus on acute leukemias Cancer Cell 1 2002 417 420
28. A.B. Goldfine, D.C. Simonson, F. Folli, M.-E. Patti, and C.R. Kahn Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies J. Clin. Endocrinol. Metab. 80 1995 3311 3319
29. H. Gu, and B.G. Neel The 'Gab' in signal transduction Trends Cell Biol. 13 2003 122 130
30. H. Gu, J.D. Griffin, and B.G. Neel Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells J. Biol. Chem. 272 1997 16421 16430
31. H. Gu, K. Saito, L.D. Klaman, J. Shen, T. Fleming, Y. Wang, J.C. Pratt, G. Lin, B. Lim, J.-P. Kinet, and B.G. Neel Essential role for Gab2 in the allergic response Nature 412 2001 186 190
32. H. Hanafusa, S. Torii, T. Yasunaga, K. Matsumoto, and E. Nishida Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty J. Biol. Chem. 279 2004 22992 22995
33. D.A. Harrison, R. Binari, S. Nahreini, M. Gilman, and N. Perrimon Activation of a Drosophila Janus Kinase (JAK) causes hematopoietic neoplasia and developmental defects EMBO J. 14 1995 2857 2865
34. R.G. Hawley, F.H.L. Lieu, A.Z.C. Fong, and T.S. Hawley Versatile retroviral vectors for potential use in gene therapy Gene Ther. 1 1994 136 138
35. P. Hof, S. Pluskey, S. Dhe-Paganon, M.J. Eck, and S.E. Shoelson Crystal structure of the SH2 domain phosphatase SHP-2 Cell 98 1998 441 450
36. L.R. Howe, S.J. Leevers, N. Gomez, S. Nakielny, P. Cohen, and C.J. Marshall Activation of the MAP kinase pathway by the protein kinase raf Cell 71 1992 335 342
37. ras and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro J. Exp. Med. 194 2001 57 69
38. A. Khwaja, P. Rodriguez-Viciana, S. Wennstrom, P.H. Warne, and J. Downward Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway EMBO J. 16 1997 2783 2793
39. R.A. Klinghoffer, and A. Kazlauskas Identification of a putative Syp substrate, the PDGFB receptor J. Biol. Chem. 270 1995 22208 22217
40. D.A. Largaespada, C.I. Brannan, N.A. Jenkins, and N.G. Copeland Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia Nat. Genet. 12 1996 137 143
41. D.T. Le, N. Kong, Y. Zhu, J.O. Lauchle, A. Aiyigari, B.S. Braun, E. Wang, S.C. Kogan, M.M. Le Beau, L. Parada, and K.M. Shannon Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder Blood 103 2004 4243 4250
42. S.J. Leevers, and C.J. Marshall Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein EMBO J. 11 1992 569 574
43. W. Li, R. Nishimura, A. Kashishian, A.G. Batzer, W.J.H. Kim, J.A. Cooper, and J. Schlessinger A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase Mol. Cell. Biol. 14 1994 509 517
44. Y. Liu, and L.R. Rohrschneider The Gift of Gab FEBS Lett. 515 2002 1 7
45. M.L. Loh, S. Vattikuti, S. Schubbert, M.G. Reynolds, E. Carlson, K.H. Lieuw, J.W. Cheng, C.M. Lee, D. Stokoe, and J.M. Bonifas Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis Blood 103 2004 2325 2331
46. W. Lu, D. Gong, D. Bar-Sagi, and P.A. Cole Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling Mol. Cell 8 2001 759 769
47. tum-l Jak kinase causes leukemia-like hematopoietic defects EMBO J. 14 1995 1412 1420
48. A. MacDonald, J. Scarola, J.T. Burke, and J.J. Zimmerman Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus Clin. Ther. 22 2000 B101 B121
49. M. Meister Blood cells of Drosophilla: Cell lineages and role in host defence Curr. Opin. Immunol. 16 2004 10 15
50. R.P. Million, and R.A. Van Etten The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase Blood 96 2000 664 670
51. M.G. Mohi, C. Boulton, T.-L. Gu, D.W. Sternberg, D. Neuberg, J.D. Griffin, D.G. Gilliland, and B.G. Neel Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs Proc. Natl. Acad. Sci. USA 101 2004 3130 3135
52. B.G. Neel, H. Gu, and L. Pao The "Shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem. Sci. 28 2003 284 293
53. K. Nishida, L. Wang, E. Morii, S.J. Park, M. Narimatsu, S. Itoh, S. Yamasaki, M. Fujishima, K. Ishihara, and M. Hibi Requirement of Gab2 for mast cell development and KitL/c-Kit signaling Blood 99 2002 1866 1869
54. A.M. O'Reilly, S. Pluskey, S.E. Shoelson, and B.G. Neel Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps Mol. Cell. Biol. 20 1999 299 311
55. A. Pardanani, and A. Tefferi Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders Blood 104 2004 1931 1939
56. T. Pawson, and J.D. Scott Signaling through scaffold, anchoring and adapter proteins Science 278 1997 2075 2080
57. L.A. Perkins, I. Larsen, and N. Perrimon corkscrew encodes a putative tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso Cell 70 1992 225 236
58. Y. Ren, S. Meng, L. Mei, Z.J. Zhao, R. Jove, and J. Wu Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor J. Biol. Chem. 279 2004 8497 8505
59. A. Sarkozy, E. Conti, D. Seripa, M.C. Digilio, N. Grifone, C. Tandoi, V.M. Fazio, V.D. Ciommo, B. Marino, A. Pizzuti, and B. Dallapiccola Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes J. Med. Genet. 40 2003 704 708
60. M. Sattler, M.G. Mohi, Y.B. Pride, L.R. Quinnan, N.A. Malouf, K. Podar, F. Gesbert, H. Iwaski, S. Li, and R.A. Van Etten Critical role for Gab2 in transformation by BCR/ABL Cancer Cell 1 2002 479 492
61. C.L. Sawyers Chronic myeloid leukemia N. Engl. J. Med. 340 1999 1330 1340
62. J. Schwaller, J. Frantsve, J. Aster, I.R. Williams, M.H. Tomasson, T.S. Ross, P. Peeters, L. Van Rompaey, R.A. Van Etten, and R. Ilaria Jr. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes EMBO J. 17 1998 5321 5333
63. J. Sebolt-Leopold Development of anticancer drugs targeting the MAP kinase pathway Oncogene 19 2000 6594 6599
64. L.E. Side, and K.M. Shannon Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled J. Pediatr. 130 1997 857 859
65. M. Tartaglia, E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer, I. van der Burgt, A.H. Crosby, A. Ion, and S. Jeffery Mutations in PTPN11, encoding protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat. Genet. 29 2001 465 468
66. M. Tartaglia, K. Kalidas, A. Shaw, X. Song, D.L. Musat, I. van der Burgt, H.G. Brunner, D.R. Bertola, A. Crosby, and A. Ion PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity Am. J. Hum. Genet. 70 2002 1555 1563
67. M. Tartaglia, C.M. Niemeyer, A. Fragale, X. Song, J. Buechner, A. Jung, K. Hahlen, H. Hasle, J.D. Licht, and B.D. Gelb Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia Nat. Genet. 34 2003 148 150
68. M. Tartaglia, S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, and M. Arico Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia Blood 104 2004 307 313
69. N.K. Tonks, and B.G. Neel Combinatorial control of specificity by protein-tyrosine phosphatases Curr. Opin. Cell Biol. 13 2001 182 195
70. D. Van Vactor, A.O. O'Reilly, and B.G. Neel Genetic analysis of protein tyrosine phosphatases Curr. Opin. Genet. Dev. 8 1998 112 126
71. M.J. Welham, U. Dechert, K.B. Leslie, F. Jirik, and J.W. Schrader Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3′-kinase J. Biol. Chem. 269 1994 23764 23768
72. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, and M. McHugh BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109
73. A. Zatkova, R. Ullmann, J.M. Rouillard, B.J. Lamb, R. Kuick, S.M. Hanash, S. Schnittger, C. Schoch, C. Fonatsch, and K. Wimmer Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients Genes Chromosomes Cancer 39 2004 263 276
74. Y. Zhang, T.A. Vik, J.W. Ryder, E.F. Srour, T. Jacks, K. Shannon, and D.W. Clapp Nf1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines J. Exp. Med. 187 1998 1893 1902
75. S.Q. Zhang, W.G. Tsiaris, T. Araki, G. Wen, L. Minichiello, R. Klein, and B.G. Neel Receptor-specific regulation of phosphatidyl 3′-kinase activation by the protein tyrosine phosphatase Shp2 Mol. Cell. Biol. 22 2002 4062 4072
76. S.Q. Zhang, W. Yang, M.I. Kontaridis, T.G. Bivona, G. Wen, T. Araki, J. Luo, J.A. Thompson, B.L. Schraven, M.R. Philips, and B.G. Neel Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment Mol. Cell 13 2004 341 355
77. K-pn, a homologue of the metastasis suppressor gene nm23, suppresses the Tum-l hematopoietic oncogene Nat. Genet. 4 1993 195 201